597 related articles for article (PubMed ID: 9393743)
1. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna R; Mayer LD
Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion.
Krishna R; McIntosh N; Riggs KW; Mayer LD
Clin Cancer Res; 1999 Oct; 5(10):2939-47. PubMed ID: 10537363
[TBL] [Abstract][Full Text] [Related]
3. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
4. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.
Krishna R; St-Louis M; Mayer LD
Int J Cancer; 2000 Jan; 85(1):131-41. PubMed ID: 10585596
[TBL] [Abstract][Full Text] [Related]
5. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia.
Gaber MH
J Biochem Mol Biol Biophys; 2002 Oct; 6(5):309-14. PubMed ID: 12385965
[TBL] [Abstract][Full Text] [Related]
6. Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin.
Krishna R; de Jong G; Mayer LD
Anticancer Res; 1997; 17(5A):3329-34. PubMed ID: 9413167
[TBL] [Abstract][Full Text] [Related]
7. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Bollinger P; Loor F
Cancer Res; 1991 Aug; 51(16):4226-33. PubMed ID: 1678313
[TBL] [Abstract][Full Text] [Related]
8. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
Colombo T; Gonzalez Paz O; D'Incalci M
Br J Cancer; 1996 Apr; 73(7):866-71. PubMed ID: 8611397
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
[TBL] [Abstract][Full Text] [Related]
10. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
Harasym TO; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
[TBL] [Abstract][Full Text] [Related]
11. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
13. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor.
Mayer LD; Bally MB; Cullis PR; Wilson SL; Emerman JT
Cancer Lett; 1990 Sep; 53(2-3):183-90. PubMed ID: 2208078
[TBL] [Abstract][Full Text] [Related]
14. Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models.
Watanabe T; Naito M; Oh-hara T; Itoh Y; Cohen D; Tsuruo T
Jpn J Cancer Res; 1996 Feb; 87(2):184-93. PubMed ID: 8609068
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats.
Wang JC; Liu XY; Lu WL; Chang A; Zhang Q; Goh BC; Lee HS
Eur J Pharm Biopharm; 2006 Jan; 62(1):44-51. PubMed ID: 16126379
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.
Zou Y; Ling YH; Van NT; Priebe W; Perez-Soler R
Cancer Res; 1994 Mar; 54(6):1479-84. PubMed ID: 8137251
[TBL] [Abstract][Full Text] [Related]
17. Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein.
Mayer LD; Lim KT; Hartley D
J Exp Ther Oncol; 2002; 2(2):107-20. PubMed ID: 12415627
[TBL] [Abstract][Full Text] [Related]
18. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
[TBL] [Abstract][Full Text] [Related]
19. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
Krishna R; Webb MS; St Onge G; Mayer LD
J Pharmacol Exp Ther; 2001 Sep; 298(3):1206-12. PubMed ID: 11504822
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
